Nexalin Technology shares are trading higher after the company announced clinical study data in major depressive disorder and publication of clinical trial results in leading scientific journal 'Brain Stimulation'
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology shares surged following the announcement of positive clinical study data for major depressive disorder and the publication of clinical trial results in the journal 'Brain Stimulation'.
June 26, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology shares surged after the company announced positive clinical study data for major depressive disorder and the publication of these results in the scientific journal 'Brain Stimulation'.
The positive clinical study data and publication in a leading scientific journal are likely to boost investor confidence in Nexalin Technology's product pipeline, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100